Next Article in Journal
Telmisartan Loaded Nanofibers Enhance Re-Endothelialization and Inhibit Neointimal Hyperplasia
Next Article in Special Issue
Oral Immunogenicity of Enterotoxigenic Escherichia coli Outer Membrane Vesicles Encapsulated into Zein Nanoparticles Coated with a Gantrez® AN–Mannosamine Polymer Conjugate
Previous Article in Journal
Green Synthesized Silver Nanoparticles Using Tridax Procumbens for Topical Application: Excision Wound Model and Histopathological Studies
Previous Article in Special Issue
Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States
Review

Targeting the Gut Mucosal Immune System Using Nanomaterials

Fischell Department of Bioengineering, University of Maryland, 8278 Paint Branch Drive, College Park, MD 20742, USA
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Yonghyun Lee
Pharmaceutics 2021, 13(11), 1755; https://doi.org/10.3390/pharmaceutics13111755
Received: 16 September 2021 / Revised: 12 October 2021 / Accepted: 15 October 2021 / Published: 21 October 2021
(This article belongs to the Special Issue Drug Delivery Systems for Oral Immunotherapy)
The gastrointestinal (GI) tract is one the biggest mucosal surface in the body and one of the primary targets for the delivery of therapeutics, including immunotherapies. GI diseases, including, e.g., inflammatory bowel disease and intestinal infections such as cholera, pose a significant public health burden and are on the rise. Many of these diseases involve inflammatory processes that can be targeted by immune modulatory therapeutics. However, nonspecific targeting of inflammation systemically can lead to significant side effects. This can be avoided by locally targeting therapeutics to the GI tract and its mucosal immune system. In this review, we discuss nanomaterial-based strategies targeting the GI mucosal immune system, including gut-associated lymphoid tissues, tissue resident immune cells, as well as GI lymph nodes, to modulate GI inflammation and disease outcomes, as well as take advantage of some of the primary mechanisms of GI immunity such as oral tolerance. View Full-Text
Keywords: gastrointestinal tract; lymph node; gut-associated lymphoid tissues; immunotherapy; vaccine; lectins; microfold (M) cells gastrointestinal tract; lymph node; gut-associated lymphoid tissues; immunotherapy; vaccine; lectins; microfold (M) cells
Show Figures

Figure 1

MDPI and ACS Style

McCright, J.; Ramirez, A.; Amosu, M.; Sinha, A.; Bogseth, A.; Maisel, K. Targeting the Gut Mucosal Immune System Using Nanomaterials. Pharmaceutics 2021, 13, 1755. https://doi.org/10.3390/pharmaceutics13111755

AMA Style

McCright J, Ramirez A, Amosu M, Sinha A, Bogseth A, Maisel K. Targeting the Gut Mucosal Immune System Using Nanomaterials. Pharmaceutics. 2021; 13(11):1755. https://doi.org/10.3390/pharmaceutics13111755

Chicago/Turabian Style

McCright, Jacob, Ann Ramirez, Mayowa Amosu, Arnav Sinha, Amanda Bogseth, and Katharina Maisel. 2021. "Targeting the Gut Mucosal Immune System Using Nanomaterials" Pharmaceutics 13, no. 11: 1755. https://doi.org/10.3390/pharmaceutics13111755

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop